BLM and breast carcinoma: Specifically, downregulation of KIF2C, POLQ, POLD1, CCNE1, ATM, RAD54L, BLM, NETO2, FZD9, CXCL5, and VIT and upregulation of ADM, BTG2, C5orf38, CDKN1C, CYP4F3, ST6GALNAC2, and SLC44A4 are the reported signatures of HRD breast cancer (Liao et al., 2021; Peng et al., 2014).